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ABSTRACT 
Background and Objectives: We sought to determine the frequency of use and 
association between prasugrel and outcomes in acute coronary syndrome (ACS) 
patients undergoing percutaneous coronary intervention (PCI) in clinical practice. 
Methods: PROMETHEUS was a multicenter observational registry of ACS PCI patients 
from 8 centers in the United States that maintained a prospective PCI registry for patient 
outcomes. The primary endpoint was major adverse cardiovascular events (MACE) at 
90 days, a composite of all cause death, non-fatal myocardial infarction, stroke or 
unplanned revascularization. Major bleeding was defined as any bleeding requiring 
hospitalization or blood transfusion. Hazard ratios were generated using multivariable 
Cox regression and stratified by the propensity to treat with prasugrel.  
Results: Out of 19914 patients (mean age 64.4 years and 32% female), 4058 received 
prasugrel (20%) and 15856 received clopidogrel (80%). Prasugrel-treated patients were 
younger with fewer comorbid risk factors compared with their counterparts receiving 
clopidogrel. At 90 days, there was a significant association between prasugrel use and 
lower MACE (5.7% vs. 9.6%, HR 0.58: 95% CI 0.50-0.67; p < 0.0001) and bleeding 
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(1.9% vs. 2.9%, HR 0.65: 95% CI 0.51-0.83; p<0.001).  After propensity stratification, 
associations were attenuated and no longer significant for either outcome.  Results 
remained consistent using different approaches to adjusting for potential confounders. 
Conclusions: In contemporary clinical practice, patients receiving prasugrel tend to 
have a lower-risk profile compared with those receiving clopidogrel.  The lower ischemic 
and bleeding events associated with prasugrel use were no longer evident after 
accounting for these baseline differences.  
INTRODUCTION 
Dual antiplatelet therapy (DAPT) with aspirin and an inhibitor of the platelet P2Y12 
receptor is standard therapy for prevention of thrombotic complications after 
percutaneous coronary intervention (PCI).1, 2 Significant genetic and pharmacodynamic 
variability exists in the response to clopidogrel and lower levels of platelet inhibition may 
be observed in some patients leading to increased risk for thrombotic events 3-5. This 
variability is overcome by prasugrel, which demonstrated superior efficacy over 
clopidogrel in the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing 
Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction (TRITON-TIMI) 
38 trial.5-7 However, compared with clopidogrel, prasugrel is associated with higher 
rates of major bleeding, particularly in elderly, low body weight patients and those with 
prior stroke or transient ischemic attack.7  
Despite these randomized results, the prospective observational Treatment With 
Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of 
Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) 
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study evaluating 12,000 myocardial infarction (MI) patients undergoing PCI in the US, 
did not demonstrate an association between prasugrel and lower MACE compared with 
clopidogrel.8, 9 In contrast, a retrospective analysis of ACS patients undergoing PCI 
(ACS-PCI) in the Premier Healthcare Alliance claims database reported lower 
readmission rates for MI or bleeding with prasugrel compared with clopidogrel.10, 11 
Whether these divergent results reflect differences in underlying patient case-mix, 
methodologic assumptions or study design remains unclear.  This issue is clinically 
relevant as the real-world application, and the putative benefit or harm, of therapeutic 
interventions may not always conform to the controlled settings of a randomized study. 
This has important implications for informing processes of care, quality and outcomes.  
Accordingly, we sought to examine the overall use and effect of prasugrel compared 
with clopidogrel in a large and contemporary registry of unselected real world ACS 
patients undergoing PCI.12, 13 
METHODS 
Population 
PROMETHEUS was a retrospective cohort study including patients presenting with 
ACS managed with PCI from 8 academic medical centers in the US between January 
1st 2010 to June 30th 2013. The study period was selected based on the approval and 
availability of prasugrel in the US market in mid- 2009, which allowed for initial uptake of 
the drug and the need for a minimum 90-day follow-up in this population.  We included 
adult patients presenting across the entire spectrum of ACS undergoing PCI with stent 
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implantation receiving either clopidogrel or prasugrel at the time of PCI.  Patients 
receiving both agents in the peri-procedural period were excluded.  
The primary objective of this study was to compare the effectiveness of a treatment 
strategy initiating prasugrel relative to clopidogrel at the time of PCI in a usual care 
environment from academic centers in the US. The selected academic centers maintain 
institutional databases prospectively recording baseline and procedural characteristics 
and clinical outcomes for PCI patients, irrespective of clinical presentation. The 
participating centers ran a query in their PCI database to identify all patients presenting 
with ACS who received prasugrel or clopidogrel during the study period. The data 
elements that were abstracted conform to the definitions used in the NCDR CathPCI 
registry data collection form version 4.4.  Follow-up was performed at each participating 
center by trained research personnel via phone call, in-person visit or medical record 
review and either occurred at regular intervals or during standard of care post-PCI 
clinical visits. All sites confirmed that relevant baseline and follow-up data on clinical 
endpoints up to one year was collected in each respective database using a pre-study 
feasibility questionnaire.   
To facilitate data extraction, the study investigators first developed a pre-specified 
extraction list of relevant baseline and outcome variables.  This list was then 
disseminated to each individual site as a platform to extract the corresponding elements 
from the database at each participating center.  After extraction, data were validated, 
examined for completeness and quality by the Data Coordinating Center at Mount Sinai, 
and aggregated to form one unified dataset upon which all analyses were performed 
(Figure 1).  Study sponsors (Daiichi Sankyo and Ei Lilly) had no access to patient level 
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data.  Details of the study organization, participating centers and investigators are 
shown in the Supplementary Appendix (Tables S1 and S2). 
End Points and Definitions 
The pre-specified primary endpoint was major adverse cardiovascular events (MACE) 
defined as a composite of all-cause death, MI, stroke or unplanned coronary 
revascularization at 90 days from index hospital PCI.  In part, this time point was chosen 
as it was not possible to monitor drug compliance post hospital discharge and we 
assumed that the adherence rate would be high while the switching rate would be low (≤ 
10%) at 90 days versus a later time interval (i.e. one year). In addition, based upon prior 
analyses from the TRITON-TIMI 38 trial, the therapeutic effect of prasugrel is largely 
evident within 90 days.14  The secondary endpoints included individual components of 
MACE, as well as MACE and its components at 1 year. Exploratory analyses were also 
performed for the composite outcome of all-cause death, MI or stroke at 90 days and 1 
year. The primary safety endpoint was major bleeding, defined as any clinically overt 
hemorrhage requiring hospitalization or blood transfusion. 
 
Statistical analysis 
Patients were grouped according to prasugrel or clopidogrel treatment at time of PCI, 
defined as receipt of medication 24 hours prior to and during the PCI procedure in 
accordance with NCDR definitions. Baseline clinical and procedural characteristics were 
compared between prasugrel and clopidogrel groups using the Student’s t-test and chi-
square test and for continuous and categorical variables, respectively.  The cumulative 
incidence of adverse events was calculated as a Kaplan-Meier estimate of time to first 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
7 
 
event and comparisons between groups were performed using the log-rank test. Two-
tailed p values of <0.05 were considered significant. Statistical analyses were performed 
using SAS version 9.3 (Cary, NC) and Stata version 12.1 (College Station, TX). 
 
 
Multivariable and propensity adjustment  
To evaluate the associations between treatment group (prasugrel vs. clopidogrel) and 
the primary outcome, hazard ratios were generated using Cox proportional hazards 
regression stratified by the propensity to receive prasugrel. Propensity scores were 
calculated using a multivariable logistic regression model with the dependent outcome 
as treatment with prasugrel (vs. clopidogrel).  The propensity model was generated in 
an iterative fashion using the method of Rosenbaum et al.15  In addition to age and sex, 
this model included all baseline covariates demonstrating significant differences 
(p<0.05) between groups and additional variables that may be plausibly related to either 
the outcome or exposure. The final propensity model included the following main 
effects: center, coronary artery disease (CAD) presentation, diabetes, age, age 
squared, bivalirudin, smoking, gender, African-American race, hypertension, family 
history of CAD, prior PCI, prior coronary artery bypass surgery (CABG), prior peripheral 
arterial disease, prior congestive heart failure, prior cerebrovascular disease (CVD), 
stent length, stent diameter, glycoprotein IIb/IIIa inhibitor use, hypercholesterolemia, 
prior myocardial infarction, estimated glomerular filtration rate, stent type, body mass 
index (BMI), hemoglobin and the following interaction terms: center*procedural 
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glycoprotein IIb/IIIa inhibitor use; BMI*hemoglobin; prior CVD*prior PCI; prior CVD*prior 
CABG. The overall c-statistic for the propensity model was 0.81. 
From this propensity model, each observation was assigned a predicted probability for 
prasugrel treatment. The distribution of propensity scores for the entire cohort and each 
treatment group were visually examined.  Mutually exclusive strata (n=10) were then 
generated based on the propensity scores for the entire cohort, a process that was 
blinded to any outcome data in order to avoid bias in selection.  The number of strata 
and their respective cut-points were based on fulfilling previously established criteria 
and adequate balance in baseline covariates.16, 17 
The adjusted associations between treatment groups and the primary MACE outcome 
at 90 days were calculated using Cox proportional hazards regression with propensity 
stratification as the primary method of analysis.  In addition to treatment (prasugrel vs. 
clopidogrel) and study center, covariates were included to account for residual 
imbalances between groups and/or to adjust for important variables related to the 
outcome of interest.  
 
The following sensitivity analyses for the primary MACE outcome were also performed: 
multivariable adjustment, propensity matching18 and inverse probability weighting.19  A 
sensitivity analysis was also performed for the primary MACE outcome by defining 
treatment groups as only those patients receiving the same medication at the time of 
PCI and at discharge and restricted to those with out-of hospital MACE (as-treated 
analysis).   
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RESULTS 
The study sample included 19,914 ACS-PCI patients.  The mean age of the study 
population was 64.4 ± 12.3 years and 32% were women. Of this cohort, 20% (n = 4058) 
received prasugrel and 80% (15861) received clopidogrel at the time of PCI. The 
distribution by clinical presentation in the overall cohort is shown in Figure 1.  Unstable 
angina (n=11,216; 56%) was the most common presentation, followed by NSTEMI 
(n=5,412; 27%) with STEMI least common (n=3,285; 17%).  Prasugrel use varied 
across the 8 sites from a minimum of 5% to a maximum of 38%.  Loss to follow-up at 90 
days and 1 year was 8.4% and 17.1%, respectively.  
The baseline differences between patients receiving prasugrel and clopidogrel are 
shown in Table 1. Prasugrel-treated patients were younger and more often male 
compared with those receiving clopidogrel.  The frequency of comorbid conditions 
including diabetes, prior MI, prior cerebrovascular disease, chronic kidney disease and 
anemia were higher among clopidogrel treated patients.  Prasugrel was more often 
used in patients with ST-elevation myocardial infarction (STEMI) or non-ST elevation 
myocardial infarction (NSTEMI) whereas clopidogrel was used more often in USA.  As 
shown in Figure 2, the frequency of prasugrel use increased with the severity of clinical 
presentation with a maximum of 24% among those presenting with STEMI.    
Table 2 shows the procedural differences between the two groups. Angiographically, 
patients receiving prasugrel had a lower frequency of left main stem disease, fewer 
complex lesions (ACC/AHA type B2/C) and fewer lesions with moderate/severe 
calcification. In contrast prasugrel-treated patients received longer stents with a greater 
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diameter whereas patients receiving clopidogrel were more likely to have bare metal 
stents. Patients on prasugrel also received less bivalirudin but more glycoprotein IIb/IIIa 
inhibitors for procedural antithrombotic therapy.  Figure 3 displays the frequency of 
prasugrel use as a function of several established clinical or angiographic thrombotic 
risk factors (diabetes mellitus, troponin (+) ACS, stent diameter < 3.0 mm or prior MI).  
While prasugrel was used in over 20% of patients with none or one such risk factor, use 
was paradoxically lowest (13.4%) among those with 4 thrombotic risk factors.  
Unadjusted MACE rates at 90 days were 5.7% and 9.6% among those receiving 
prasugrel and clopidogrel, respectively (Table 3 and Figure 4, p<0.001). Associations 
were attenuated and no longer statistically significant after adjusting for the propensity 
to receive prasugrel (HR 0.89; 95% CI: 0.76-1.05; p=0.16).  The adjusted point 
estimates were concordant using different analytic methods (propensity matching, 
inverse probability weighting [IPW] and covariate adjustment, respectively).  IPW gave a 
less precise estimate, likely due to undue influence of a few patients with very large 
weights.  Associations for most other endpoints at 90 days followed a similar pattern 
with large and significant unadjusted reductions attenuating to more modest differences 
after adjustment. 
At 365 days, reductions in MACE associated with prasugrel use were slightly larger in 
magnitude compared with those observed at 90 days (Table 3 and Figure 4) and 
remained significant after propensity stratification (HR for MACE: 0.86; 95% CI: 0.77-
0.96).  In contrast, no significant differences were observed between groups for both MI 
and bleeding at 365 days. 
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Results for the exploratory outcome of death, MI or stroke demonstrate significant 
reductions associated with prasugrel use at 90 and 365 days using propensity 
stratification and covariate adjustment.  In contrast results were non-significantly 
different for this outcome using IPW (Table 3). 
Supplementary Table 3 shows the results after including those patients receiving the 
same medication at the time of PCI and at hospital discharge (as-treated analysis). 
These results demonstrate comparable results to those obtained in the overall 
population with unadjusted reductions in risk associated with prasugrel use diminishing 
upon adjustment.  
Discussion 
Salient findings from this report of prasugrel use in contemporary clinical practice 
include: (i) use of prasugrel was relatively uncommon in an ACS PCI setting despite 
evidence from clinical trials - although use was higher among those with troponin 
positive syndromes; (ii) patients receiving prasugrel were younger and highly selected 
with fewer comorbidities compared with their counterparts receiving clopidogrel and the 
decision to use prasugrel appears to be strongly influenced by the warnings in the US 
product insert; (iii) unadjusted risks for both ischemic and bleeding complications were 
substantially lower among those receiving prasugrel compared to clopidogrel; (iv) 
differences in adverse events were attenuated and no longer significant at 90 days after 
adjusting for baseline imbalances between groups.  Taken together, the current findings 
represent the first cohort study using real-world data from academic medical centers 
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across the US to study the use and outcome of prasugrel as compared with clopidogrel 
in patients across the entire ACS clinical spectrum undergoing PCI. 
 
In the TRITON-TIMI 38 randomized trial, prasugrel reduced ischemic events by a 19%, 
albeit at an excess cost of bleeding, among ACS patients undergoing PCI.7  Consistent 
with these randomized data, our results show lower 90 day and one-year MACE rates 
with prasugrel before and after adjustment, although adjusted differences at 90 days 
were modest and not statistically significant.  The magnitude and direction of benefit 
was largely consistent across the different analytic approaches.   
There are several possibilities that might reconcile the divergent results between 
earlier randomized trial data and our observational findings.  First, the proportion of 
patients who might be expected to derive the largest benefit at 90 days from potent 
platelet inhibition (i.e. STEMI) comprised only 17% of the PROMETHEUS cohort 
whereas 26% of patients enrolled in TRITON-TIMI 38 presented with STEMI.7, 20, 21  
Second, it is possible that the relatively low-risk patients selected to receive prasugrel in 
a real-world setting may not derive or even require the same degree of therapeutic 
protection compared to those enrolled in randomized trials (i.e. risk/treatment 
paradox).22, 23 Indeed, the frequency of many clinical risk factors that are associated 
with substantial thrombotic risk, including diabetes mellitus, prior MI and small stent 
diameter were substantially lower among those treated with prasugrel compared to 
clopidogrel.  Moreover, although prasugrel use increased by clinical severity, only 24% 
of STEMI patients received this agent. Such selected use of prasugrel is consistent with 
the results of the prospective TRANSLATE-ACS registry, which also showed a similar 
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imbalance in underlying risk factors among MI patients treated with prasugrel compared 
to clopidogrel.8  Clearly, further study is needed to explore the determinants of clinical 
decision-making at the time of PCI as our results, similar to TRANSLATE-ACS, suggest 
that a more potent treatment is being used in patients with a lower likelihood to derive 
meaningful benefit.8, 24 Whether or not recalibrating the intensity of antiplatelet 
pharmacotherapy to more closely approximate a patient’s inherent thrombotic risk is a 
hypothesis that warrants further study.25 
In exploratory analyses we observed a significant 25% reduction in the 
composite occurrence of all-cause death, MI or stroke at 90 days associated with 
prasugrel use, a magnitude of benefit virtually identical to that observed in TRITON-TIMI 
38 using a similar outcome and time point. Nevertheless, the magnitude and direction of 
effect for the individual components that drove this composite endpoint varied 
substantially, with important implications for interpreting and comparing such results 
across studies.  More specifically, in TRITON-TIMI 38 prasugrel use led to significant 
reductions in MI, not death, whereas in PROMETHEUS adjusted reductions in MI at 90 
and 365 days were non-significant.  In contrast, we observed significant reductions in 
all-cause mortality associated with prasugrel use in both unadjusted and adjusted 
analyses.  Hence, contrasting effects on individual endpoints across studies yielded 
similar estimates for a composite outcome that included those very components.   
The reductions in death observed in PROMETHEUS may be attributable to 
selection bias, coupled with a modest reduction in ischemic events without concordant 
excess bleeding risk.  With respect to the former, it is possible that residual or 
unmeasured confounding strongly influenced the mortality point estimates as prasugrel-
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treated patients were much healthier compared with those receiving clopidogrel.  In 
support of the latter, it is plausible that a modest reduction in MACE risk in the absence 
of bleeding harm may confer a mortality advantage.  This hypothesis remains 
speculative, however, as the reductions in MI and MACE were numerically lower 
compared with mortality and without statistical significance.  As a result it is unlikely that 
similar findings to ours will be duplicated, as the associations with death were observed 
absent a concordant reduction in other ischemic events.  
Unadjusted bleeding rates were also significantly lower among prasugrel versus 
clopidogrel-treated patients in our study, findings that are consistent with TRANSLATE-
ACS and are most likely attributable to the lower risk profile of patients selected to 
receive prasugrel.8  At one year the absolute differences in bleeding rates in favor of 
prasugrel in our study and TRANSLATE-ACS were 1.7% and 1.0%, respectively.8  This 
suggests that prasugrel-treated patients in PROMETHEUS were somewhat healthier 
and at lower risk for bleeding compared with their counterparts in the TRANSLATE-ACS 
study, further supporting the inclusion of a more selected cohort unlikely to manifest 
overt bleeding risk. After adjustment, however, hazard ratios for bleeding were not 
significantly different between groups.  Differences in patient populations, bleeding 
ascertainment, and/or selection bias may account for the inconsistent results between 
studies.  For example, we relied on bleeding-related hospitalizations as our safety 
endpoint whereas bleeding was prospectively ascertained and adjudicated in 
TRANSLATE-ACS.  Therefore, under reporting of bleeding may have biased our results 
to the null.  Alternatively, real-world selection for prasugrel use may be largely driven by 
factors that correlate with bleeding propensity rather than ischemic risk, resulting in the 
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treatment of patients both unlikely to manifest overt harm but also not experience any 
meaningful benefit.26 
 
Limitations 
Among the important limitations of our study was the observational retrospective design, 
thereby precluding causal inferences.  Although we used several statistical methods to 
account for the substantial imbalances between treatment groups, we cannot exclude 
the possibility of residual or unmeasured confounders influencing our estimates.  
However, our findings were consistent in both direction and magnitude across the 
different adjustment techniques.  In the absence of standard prospective data collection 
that was uniform across study centers we may have underestimated the rates of some 
clinical events.  Detailed data on medication adherence, an important determinant of 
risk after PCI, was not available across centers.  Although we used an early time point 
of 90 days for our primary analysis, we were unable to account for therapeutic cross-
over and/or compliance in the follow-up period after hospital discharge.  In addition, 
granular information on timing of medication administration relative to diagnostic 
angiography and PCI was not available.  Although ticagrelor was approved for use in 
7/2011, which coincides with the inclusion period for our study, we directed each center 
to only provide data on patients treated with either clopidogrel or prasugrel in 
accordance with the study aims and objectives.  While we may have excluded certain 
patients treated with ticagrelor in the latter 2 years of the study period, administrative 
data describing national trends in P2Y12 inhibitor use during this time frame are largely 
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consistent with our results in that clopidogrel was the most commonly used drug 
followed by prasugrel with ticagrelor used least frequently.27, 28      
 
Conclusions 
In a large, real-world cohort of ACS patients undergoing PCI at medical centers across 
the US we observed that prasugrel is used infrequently and in much lower risk patients 
compared with those receiving clopidogrel.  Large reductions in risk for both ischemic 
and bleeding complications associated with prasugrel use were no longer apparent after 
considering baseline differences between groups.  Recalibrating ‘real-world’ use of 
prasugrel to better approximate a patient’s ischemic risk may yield a more appreciable 
therapeutic benefit, a hypothesis that warrants further study. 
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Figure Legends 
Figure 1 Frequency of Clinical Presentation in PROMETHEUS Cohort 
Pie chart displays the overall frequency and number of patients presenting with unstable 
angina, non ST-segment elevation myocardial infarction and ST-segment myocardial 
infarction in the PROMETHEUS cohort. 
 
Figure 2 Frequency of Prasugrel Use By Clinical Presentation 
Bar graph depicts the frequency of prasugrel use according to clinical presentation.  
 
Figure 3 Frequency of Prasugrel Use By Number of Thrombotic Risk Factors 
Thrombotic risk factors include presentation with troponin (+) syndrome, diabetes 
mellitus, prior myocardial infarction or stent diameter < 3.0 mm.  Vertical bars display 
the frequency of prasugrel use according to the total number of thrombotic risk factors 
among patients. 
 
Figure 4 Cumulative Major Adverse Cardiovascular Events and Bleeding by 
Treatment Group 
Kaplan-Meier curves displaying the cumulative rate of major adverse cardiovascular 
events (MACE; composite of all-cause death, myocardial infarction, stroke or unplanned 
coronary revascularization – panel A) and bleeding (panel B) by treatment group at 90 
and 365 days
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Table 1: Baseline Clinical Characteristics by Treatment Group 
 Prasugrel 
(n = 4058) 
Clopidogrel 
(n = 15856) p 
Age, years 58.7 ± 10.3 65.8 ± 12.3 <0.0001 
Female sex, n (%) 989 (24.4%) 5315 (33.5%) <0.0001 
African-American, n (%) 253 (6.2%) 1,872 (11.8%) <0.0001 
BMI (kg/m
2
) 30.7 ± 6.2 29.7± 6.2 <0.0001 
Diabetes, n (%) 1382 (34.1%) 6198 (39.1%) <0.0001 
Diabetes on insulin, n (%) 394 (9.7%) 2140 (13.5%) <0.0001 
Hypertension, n (%) 2915 (71.8%) 13466 (84.9%) <0.0001 
Dyslipidemia, n (%) 3220 (79.3%) 13469 (84.9%) <0.0001 
Smoking, n (%) 1175 (29.0%) 3831 (24.2%) <0.0001 
Prior MI, n (%) 833 (20.5%) 5130 (32.4%) <0.0001 
Prior PCI, n (%) 788 (19.4%) 4250 (26.8%) <0.0001 
Prior CABG, n (%) 359 (8.8%) 3074 (19.4%) <0.0001 
Prior cerebrovascular disease 188 (4.6%) 2197 (13.9%) <0.0001 
Prior CHF, n (%) 567 (14.0%) 3684 (23.2%) <0.0001 
Prior PAD, n (%) 291 (7.2%) 2140 (13.5%) <0.0001 
CKD, n (%) 619 (15.3%) 4994 (31.5%) <0.0001 
Anemia, n (%) 339 (8.4%) 2553 (16.1%) <0.0001 
CAD Presentation, n (%)    
STEMI 773 (19.0%) 2512 (15.8%) <0.0001 
NSTEMI 1159 (28.6%) 4253 (26.8%) 0.03 
Unstable Angina 2,126 (52.4%) 9090 (57.3%) <0.0001 
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BMI: Body Mass Index; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery By-pass; graft; CHF: Congestive Heart Failure; PAD: 
Peripheral Artery Disease; CKD: Chronic Kidney Disease; CAD: Coronary Artery Disease; STEMI: ST segment elevation myocardial infarction; NSTEMI: Non ST-
segment elevation myocardial infarction; ACIE: Angiotensin-Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker 
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Table 2: Baseline Procedural Characteristics by Treatment Group 
 Prasugrel 
(n = 4058) 
Clopidogrel 
(n = 15856) P 
Multivessel disease, n (%) 1672 (41.2%) 6724 (42.4%) 0.17 
PCI vessel    
Left Main, n (%) 84 (2.1%) 583 (3.7%) <0.0001 
LAD, n (%) 1972 (48.6%) 6923 (43.7%) <0.0001 
Circumflex, n (%) 1100 (27.1%) 4794 (30.2%) <0.0001 
RCA, n (%) 1430 (35.2%) 5367 (33.9%) 0.097 
B2/C type lesion, n (%) 2848 (70.2%) 10758 (67.8%) <0.0001 
Moderate to severe calcification, n (%) 422 (10.4%) 2349 (14.8%) <0.0001 
Bifurcation lesion, n (%) 446 (11.0%) 1676 (10.6%) 0.38 
Total stent length, mm 31.4 ± 20.2 30.50 ± 20.9 0.016 
Minimum stent diameter, mm 3.01 ± 0.49 2.96 ± 0.50 <0.0001 
At least one 1
st
 gen DES, n (%) 297 (7.3%) 2495 (15.7%) <0.0001 
At least one 2
nd
 gen DES, n (%) 3283 (80.9%) 10278 (64.8%) <0.0001 
At least one BMS, n (%) 569 (14.0%) 3926 (24.8%) <0.0001 
Procedural anticoagulation     
  Bivalirudin, n (%) 2743 (67.6%) 11726 (74.0%) <0.0001 
  GPIIb/IIIa inhibitor, n (%) 1178 (29.0%) 3388 (21.4%) <0.0001 
  LMWH, n (%) 38 (0.9%) 169 (1.1%) 0.77 
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Table 3.  Crude Event Rates, Unadjusted and Adjusted Associations for Adverse Events 
 Treatment group* Hazard ratios (95% Confidence Interval) 
 Prasugrel 
(n=4,058) 
Clopidogrel 
(n=15,856) 
Unadjusted 
Propensity 
stratified
1
 
IPW Covariate Adjusted 
90 Days       
    MACE – Primary endpoint, n (%) 216 (5.7%) 1,415 (9.6%) 0.58 (0.50-0.67) 0.89 (0.76-1.05) 0.94 (0.76-1.16) 0.94 (0.80-1.09) 
Death, Myocardial Infarction or Stroke, n (%) 101 (2.7%) 1,000 (6.8%) 0.39 (0.31-0.47) 0.75 (0.60-0.94) 0.82 (0.61-1.11) 0.77 (0.61-0.96) 
    Death, n (%) 23 (0.6%) 408 (2.8%) 0.21 (0.10-0.30) 0.62 (0.40-0.99) 0.52 (0.3-0.94) 0.68 (0.44-1.05) 
    Myocardial Infarction, n (%) 74 (1.9%) 562 (3.8%) 0.51 (0.40-0.64) 0.84 (0.64-1.11) 1.1 (0.76-1.55) 0.84 (0.65-1.10) 
Unplanned revascularization, n (%) 138 (3.7%) 586 (4.1%) 0.89 (0.75-1.08) 1.06 (0.86-1.31) 1.21 (0.92-1.58) 1.05 (0.85-1.28) 
    Bleeding, n (%) 75 (1.9%) 442 (2.9%) 0.65 (0.51-0.83) 1.03 (0.78-1.36) 1.01 (0.69-1.48) 1.03 (0.79-1.35) 
365 Days       
MACE, n (%) 433 (12.1%) 2,866 (20.6%) 0.56 (0.50-0.62) 0.86 (0.77-0.96) 0.91 (0.79-1.06) 0.85 (0.76-0.95) 
Death, Myocardial Infarction or Stroke, n (%) 199 (5.6%) 1,778 (12.8%) 0.42 (0.36-0.48) 0.83 (0.71-0.98) 0.89 (0.72-1.10) 0.80 (0.68-0.94) 
Death, n (%) 62 (1.8%) 901 (6.6%) 0.26 (0.20-0.33) 0.69 (0.52-0.91) 0.63 (0.43-0.91) 0.67 (0.51-0.87) 
    Myocardial Infarction, n (%) 122 (3.3%) 855 (6.1%) 0.54 (0.44-0.65) 0.90 (0.72-1.11) 1.13 (0.86-1.49) 0.86 (0.70-1.06) 
Unplanned revascularization, n (%) 300 (8.5%) 1,507 (11.5%) 0.74 (0.65-0.84) 0.92 (0.80–1.06) 1.00 (0.84-1.20) 0.88 (0.77-1.01) 
    Bleeding, n (%) 112 (3.1%) 664 (4.7%) 0.64 (0.52-0.78) 0.97 (0.78-1.22) 0.86 (0.63-1.18) 0.96 (0.77-1.19) 
IPW – inverse probability weighting; MACE – major adverse cardiovascular events (all-cause death, myocardial infarction, stroke or unplanned revascularization); *Event rates calculated as Kaplan-
Meier estimates at different time points.
1
Propensity stratification is the pre-specified primary method of adjustment.  It is based on dividing the patient population into 10 strata based on the 
distribution of patient propensity score
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